Psy-COH - French Cohort of Three Major Psychiatric disorders: Schizophrenia, Bipolar disorders, and Asperger syndrome

Head :Leboyer Marion

Last update : 02/10/2014 Version : 1 ID : 3145		
General		
Identification		
Detailed name	French Cohort of Three Major Psychiatric disorders: Schizophrenia, Bipolar disorders, and Asperger syndrome	
Sign or acronym	Psy-COH	
General Aspects		
Medical area	Psychology and psychiatry	
Health determinants	Addictions Genetic Geography Social and psychosocial factors	
Others (details)	Schizophrenia, Bipolar disorders, ans Asperger syndrome	
Scientific investigator(s) (Contact)		
Name of the director	Leboyer	
Surname	Marion	
Email	marion.leboyer@inserm.fr	
Organization	Fondation FondaMental - UPEC - Inserm	
Collaborations		
Funding		
Funding status	Mixed	
Details	ANR "Investissements d'avenir", Sanofi	
Governance of the database		
Sponsor(s) or organisation(s) responsible	Fondation FondaMental	

Organisation status	Private
Sponsor(s) or organisation(s) responsible	Université Paris-est-Créteil (UPEC) - Université Pierre et Marie Curie (UPMC)
Organisation status	Public
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Database objective	
Main objective	 Improve our ability to offer early diagnosis and prevention through identification of valid biomarkers/ bio-signatures of three major mental disorders Identify trajectories of patients moving across stages of disorder and behavioural indicators and biomarkers predecting risk and prognosis Estimate utilization of services, healthcare, societal costs and quality of life of patients suffering from these three disorders Allow national and international academic collaborators or industry partners to access cohort or data collected, to accelerate scientific progress.
Main objective Inclusion criteria	prevention through identification of valid biomarkers/ bio-signatures of three major mental disorders 2. Identify trajectories of patients moving across stages of disorder and behavioural indicators and biomarkers predecting risk and prognosis 3. Estimate utilization of services, healthcare, societal costs and quality of life of patients suffering from these three disorders 4. Allow national and international academic collaborators or industry partners to access cohort
	prevention through identification of valid biomarkers/ bio-signatures of three major mental disorders 2. Identify trajectories of patients moving across stages of disorder and behavioural indicators and biomarkers predecting risk and prognosis 3. Estimate utilization of services, healthcare, societal costs and quality of life of patients suffering from these three disorders 4. Allow national and international academic collaborators or industry partners to access cohort or data collected, to accelerate scientific progress. Young patients -between 16 and 35 years old - with psychotic disorders (bipolar disorders dans schizophrenia), focussing on first-episodes, as well as neuro-developmental disorders (autism without mental retardation, or Aspeger, aged 3 years and

	Adulthood (45 to 64 years)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Patients will be recruited in the expert centers involved in the french network. This network is composed of 8 bipolar disorders (Bordeaux, Créteil, Grenoble, Marseille, Montpellier, Paris, Strasbourg, Versailles), 8 for schizophrenia (Clermont-Ferrand, Créteil, Lyon, Marseille, Montpellier, Paris, Strasbourg, Versailles) and 4 for Asperger syndrome (Bordeaux, Créteil, Paris, Toulouse)
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2012
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	We aim to recruit 1000 bipolar, 800 schizophrenic, and 200 Asperger patients.
Data	
Database activity	Current data collection
Type of data collected	Clinical data Declarative data Paraclinical data Biological data
Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Paper self-questionnaire

Brain imaging

NFS, blood gases, electrolytes, glycemia, lipid profile, normal liver chemistry, thyroid profile, albumin, total protein, urea, uric acid, creatinine,

phosphorus, iron, serum calcium level,

Paraclinical data (detail)

Biological data (detail)

psychotropic dosages, ...

Presence of a biobank

Yes

Contents of biobank

Whole blood Serum Plasma DNA DNAc/RNAm

Details of biobank content

The collections will be constituted of different biosamples all derived from blood: DNA for genetic and epigenetic studies, RNA and lymphocytes for transcriptomics, serum for proteomics and metabolomics analyses. Blood sampling will be performed first at inclusion for each of the 2000 expected subjects, and then on a yearly basis during the clinical follow-up. On the contrary to others specimen, lymphoblastoid cell lines will be established only once at first inclusion. Blood will be collected in tubes supplemented with EDTA for DNA extraction, with lithium heparin for lymphocyte isolation, in silicone costed for serum and in PAXgene collection tubes for RNA extraction

Health parameters studied

Health event/morbidity
Health care consumption and services
Quality of life/health perception

Care consumption (detail)

Hospitalization Medical/paramedical consultation Medicines consumption

Procedures

Data collection method

An anomized e-medical file has been created, that allow data recording and sharing between centres. Three e-medical files (e-Fondamental) allow extensive psychaitric, somatic and cognitive assesments, conducted by trained psychiatrists, psychologists and nurses. Three e-medical files (ebipolar, e-schizo, and e-asperger) have already been built for assesment and follow-up of each disorder which allow the implementation of a personalized approach to the care and treatment of each patient, shared with the referring clinicians (MG and psychiatrists). In addition to its clinical remits, the network has begun to develop largescale datasets along with biobanks or repositories, linked with platforms for genotyping or brainimaging.

Participant monitoring

Yes

Details on monitoring of participants	We plan to follow-up during ten years the impact of environemental factors (such as stress, migration, urban condition, cannabis), and to use innovative medical devices to examine objective parameters that might be associated with risk and relapse such as indicators of circadian rhythm (actimetry, web based diary, as well as body monitor), but also indicators of somatic disorders (weight, biological tests). Blood sampling will be performed every year to follow up native DNA and RNA to explore the possible changes of epigenetic markers during follow-up as well as immuno-inflammation parameters measured in serum
Links to administrative sources	No
Promotion and access	
Promotion	
Link to the document	http://www.fondation-fondamental.org/
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Psy-COH will allow data access to academic as well as industrial partners, thus giving birth to numerous innotiative projects
Access to aggregated data	Access on specific project only

Access on specific project only

Access to individual data